BioXcel Therapeutics Announces Initiation of Serenity at-Home Pivotal Phase 3 Safety Trial of Bxcl501 for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia
bioxcel therapeutics宣佈啓動Bxcl501急性治療雙相情感障礙或精神分裂症相關激動狀態家庭至關重要第三階段安全試驗